Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose

[No Value] Nitin, Alicia L. Carlson, Tim Muldoon, Adel K. El-Naggar, Ann Gillenwater, Rebecca Richards-Kortum

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The clinical value of assessing tumor glucose metabolism via F-18 fluorodeoxyglucose (FDG) PET imaging in oncology is well established; however, the poor spatial resolution of PET is a significant limitation especially for early stage lesions. An alternative technology is optical molecular imaging, which allows for subcellular spatial resolution and can be effectively used with topical contrast agents for imaging epithelial derived cancers. The goal of this study was to evaluate the potential of optical molecular imaging of glucose metabolism to aid in early detection of oral neoplasia. Fluorescently labeled deoxyglucose (2-NBDG (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D- glucose)) was applied topically to tissue phantoms, fresh oral biopsies (n = 32) and resected tumors specimens (n = 2). High-resolution imaging results show that 2-NBDG can be rapidly delivered to oral epithelium using topical application. In normal epithelium, the uptake of 2-NBDG is limited to basal epithelial cells. In contrast, high-grade dysplasia and cancers show uptake of 2-NBDG in neoplastic cells throughout the lesion. Following 2-NBDG labeling, the mean fluorescence intensity of neoplastic tissue averages 3.7 times higher than that of matched nonneoplastic oral biopsies in samples from 20 patients. Widefield fluorescence images of 8-paired oral specimens were obtained pre and postlabeling with 2-NBDG. Prior to labeling, neoplastic samples showed significantly lower autofluorescence than nonneoplastic samples. The fluorescence of neoplastic samples increased dramatically after labeling; the differential increase in fluorescence was on average 30 times higher in neoplastic samples than in normal samples. Topical application of 2-NBDG can therefore provide image contrast in both widefield and high-resolution fluorescence imaging modalities, highlighting its potential in early detection of oral neoplasia.

Original languageEnglish (US)
Pages (from-to)2634-2642
Number of pages9
JournalInternational Journal of Cancer
Volume124
Issue number11
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Molecular Imaging
Glucose
Optical Imaging
Neoplasms
Fluorescence
Epithelium
Biopsy
2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose
Fluorodeoxyglucose F18
Contrast Media
Epithelial Cells
Technology

Keywords

  • Epithelial cancer
  • Fluorescent glucose analogs
  • Molecular imaging
  • Oral cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Nitin, N. V., Carlson, A. L., Muldoon, T., El-Naggar, A. K., Gillenwater, A., & Richards-Kortum, R. (2009). Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose. International Journal of Cancer, 124(11), 2634-2642. https://doi.org/10.1002/ijc.24222

Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose. / Nitin, [No Value]; Carlson, Alicia L.; Muldoon, Tim; El-Naggar, Adel K.; Gillenwater, Ann; Richards-Kortum, Rebecca.

In: International Journal of Cancer, Vol. 124, No. 11, 01.06.2009, p. 2634-2642.

Research output: Contribution to journalArticle

Nitin, NV, Carlson, AL, Muldoon, T, El-Naggar, AK, Gillenwater, A & Richards-Kortum, R 2009, 'Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose', International Journal of Cancer, vol. 124, no. 11, pp. 2634-2642. https://doi.org/10.1002/ijc.24222
Nitin, [No Value] ; Carlson, Alicia L. ; Muldoon, Tim ; El-Naggar, Adel K. ; Gillenwater, Ann ; Richards-Kortum, Rebecca. / Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose. In: International Journal of Cancer. 2009 ; Vol. 124, No. 11. pp. 2634-2642.
@article{2b457cc14dcf4713827712bc3c55cdf0,
title = "Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose",
abstract = "The clinical value of assessing tumor glucose metabolism via F-18 fluorodeoxyglucose (FDG) PET imaging in oncology is well established; however, the poor spatial resolution of PET is a significant limitation especially for early stage lesions. An alternative technology is optical molecular imaging, which allows for subcellular spatial resolution and can be effectively used with topical contrast agents for imaging epithelial derived cancers. The goal of this study was to evaluate the potential of optical molecular imaging of glucose metabolism to aid in early detection of oral neoplasia. Fluorescently labeled deoxyglucose (2-NBDG (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D- glucose)) was applied topically to tissue phantoms, fresh oral biopsies (n = 32) and resected tumors specimens (n = 2). High-resolution imaging results show that 2-NBDG can be rapidly delivered to oral epithelium using topical application. In normal epithelium, the uptake of 2-NBDG is limited to basal epithelial cells. In contrast, high-grade dysplasia and cancers show uptake of 2-NBDG in neoplastic cells throughout the lesion. Following 2-NBDG labeling, the mean fluorescence intensity of neoplastic tissue averages 3.7 times higher than that of matched nonneoplastic oral biopsies in samples from 20 patients. Widefield fluorescence images of 8-paired oral specimens were obtained pre and postlabeling with 2-NBDG. Prior to labeling, neoplastic samples showed significantly lower autofluorescence than nonneoplastic samples. The fluorescence of neoplastic samples increased dramatically after labeling; the differential increase in fluorescence was on average 30 times higher in neoplastic samples than in normal samples. Topical application of 2-NBDG can therefore provide image contrast in both widefield and high-resolution fluorescence imaging modalities, highlighting its potential in early detection of oral neoplasia.",
keywords = "Epithelial cancer, Fluorescent glucose analogs, Molecular imaging, Oral cancer",
author = "Nitin, {[No Value]} and Carlson, {Alicia L.} and Tim Muldoon and El-Naggar, {Adel K.} and Ann Gillenwater and Rebecca Richards-Kortum",
year = "2009",
month = "6",
day = "1",
doi = "10.1002/ijc.24222",
language = "English (US)",
volume = "124",
pages = "2634--2642",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose

AU - Nitin, [No Value]

AU - Carlson, Alicia L.

AU - Muldoon, Tim

AU - El-Naggar, Adel K.

AU - Gillenwater, Ann

AU - Richards-Kortum, Rebecca

PY - 2009/6/1

Y1 - 2009/6/1

N2 - The clinical value of assessing tumor glucose metabolism via F-18 fluorodeoxyglucose (FDG) PET imaging in oncology is well established; however, the poor spatial resolution of PET is a significant limitation especially for early stage lesions. An alternative technology is optical molecular imaging, which allows for subcellular spatial resolution and can be effectively used with topical contrast agents for imaging epithelial derived cancers. The goal of this study was to evaluate the potential of optical molecular imaging of glucose metabolism to aid in early detection of oral neoplasia. Fluorescently labeled deoxyglucose (2-NBDG (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D- glucose)) was applied topically to tissue phantoms, fresh oral biopsies (n = 32) and resected tumors specimens (n = 2). High-resolution imaging results show that 2-NBDG can be rapidly delivered to oral epithelium using topical application. In normal epithelium, the uptake of 2-NBDG is limited to basal epithelial cells. In contrast, high-grade dysplasia and cancers show uptake of 2-NBDG in neoplastic cells throughout the lesion. Following 2-NBDG labeling, the mean fluorescence intensity of neoplastic tissue averages 3.7 times higher than that of matched nonneoplastic oral biopsies in samples from 20 patients. Widefield fluorescence images of 8-paired oral specimens were obtained pre and postlabeling with 2-NBDG. Prior to labeling, neoplastic samples showed significantly lower autofluorescence than nonneoplastic samples. The fluorescence of neoplastic samples increased dramatically after labeling; the differential increase in fluorescence was on average 30 times higher in neoplastic samples than in normal samples. Topical application of 2-NBDG can therefore provide image contrast in both widefield and high-resolution fluorescence imaging modalities, highlighting its potential in early detection of oral neoplasia.

AB - The clinical value of assessing tumor glucose metabolism via F-18 fluorodeoxyglucose (FDG) PET imaging in oncology is well established; however, the poor spatial resolution of PET is a significant limitation especially for early stage lesions. An alternative technology is optical molecular imaging, which allows for subcellular spatial resolution and can be effectively used with topical contrast agents for imaging epithelial derived cancers. The goal of this study was to evaluate the potential of optical molecular imaging of glucose metabolism to aid in early detection of oral neoplasia. Fluorescently labeled deoxyglucose (2-NBDG (2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D- glucose)) was applied topically to tissue phantoms, fresh oral biopsies (n = 32) and resected tumors specimens (n = 2). High-resolution imaging results show that 2-NBDG can be rapidly delivered to oral epithelium using topical application. In normal epithelium, the uptake of 2-NBDG is limited to basal epithelial cells. In contrast, high-grade dysplasia and cancers show uptake of 2-NBDG in neoplastic cells throughout the lesion. Following 2-NBDG labeling, the mean fluorescence intensity of neoplastic tissue averages 3.7 times higher than that of matched nonneoplastic oral biopsies in samples from 20 patients. Widefield fluorescence images of 8-paired oral specimens were obtained pre and postlabeling with 2-NBDG. Prior to labeling, neoplastic samples showed significantly lower autofluorescence than nonneoplastic samples. The fluorescence of neoplastic samples increased dramatically after labeling; the differential increase in fluorescence was on average 30 times higher in neoplastic samples than in normal samples. Topical application of 2-NBDG can therefore provide image contrast in both widefield and high-resolution fluorescence imaging modalities, highlighting its potential in early detection of oral neoplasia.

KW - Epithelial cancer

KW - Fluorescent glucose analogs

KW - Molecular imaging

KW - Oral cancer

UR - http://www.scopus.com/inward/record.url?scp=64249130154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249130154&partnerID=8YFLogxK

U2 - 10.1002/ijc.24222

DO - 10.1002/ijc.24222

M3 - Article

VL - 124

SP - 2634

EP - 2642

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 11

ER -